NCT04830345View on ClinicalTrials.gov

Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines

PHASE3CompletedINTERVENTIONAL
Enrollment

290

Participants

Timeline

Start Date

June 29, 2020

Primary Completion Date

September 1, 2021

Study Completion Date

October 1, 2021

Conditions
Glabellar Frown Lines
Interventions
BIOLOGICAL

ATGC-100 100U

Clostridium botulinum toxin type A

BIOLOGICAL

Botox 100U

Clostridium botulinum toxin type A

Trial Locations (1)

Unknown

Nowon Eulji University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

EuBiologics Co.,Ltd

INDUSTRY

NCT04830345 - Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines | Biotech Hunter | Biotech Hunter